Actinium Pharmaceuticals will present two abstracts on April 21, 2026, at the AACR Annual Meeting in San Diego in the Experimental and Molecular Therapeutics category15.
The abstracts cover preclinical data on ATNM-400, a first-in-class Actinium-225 radiotherapy targeting resistant tumors in prostate and lung cancers, including overcoming osimertinib resistance in EGFR-mutated NSCLC, and Actimab-A1.
Full abstract details will be released publicly on March 17, 2026, at 4:
30 PM ET via the AACR Online Program Planner, serving as a near-term catalyst for the stock1.
ATNM-400 targets a U.S. market of over 500,000 new prostate and lung cancer cases annually and shows potential synergy with osimertinib1.
Actimab-A is part of ongoing development for AML and myeloid malignancies, including NCI CRADA trials2.
Sources:
1. https://www.ainvest.com/news/actinium-aacr-catalyst-trading-setup-abstracts-2602/
2. https://ir.actiniumpharma.com/annual-reports/content/0001213900-25-026371/ea0232395-10k_actinium.htm